Human Visual and Vestibular Motion Perception Study
ConditionVestibular Disease
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorUniversity of Rochester
About this trial
The purpose this study is to measure sensitivity to visual and vestibular or balance motion. It is hoped that the results may help researchers better understand how aging and disease affect motion perception.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
general good health
general good health
specific unilateral or bilateral vestibular loss
Disqualifiers
subjects who are institutionalized or otherwise not self-sufficient.
enduring sequelae due to diseases of the nervous system, eyes, ears, head and neck, and limbs, except for changes commensurate with normal aging (e.g. presbyacusic hearing loss, mild cataract, etc.).
abnormal cognitive function, which if in question can be determined as a score of <27 on the Mini-Mental State test.
corrected visual acuity worse than 20/20 up to age 65, worse than 20/40 if >65
Trial design
Design model
Parallel
Treatments tested in this trial
Heading direction adaptation
BehavioralWill adapt subject's perceived heading direction using exposure to visual environments that include rotation and situations where visual and inertial heading direction are systematically offset.
Treatment groups
300 Participants
are divided into 2 treatment groupsGroup A: Healthy subjectsActive comparator 1 intervention
Group B: Vestibular Disease patientsActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Change in Mean Heading perception
Heading perception will be measured using two alternative forced choice and magnitude estimation procedures and reported in degrees. It is measured in degrees of azimuth with positive to the right and negative to the left of straight ahead (defined as 0 degrees).
Time frame
Baseline to 1 weekSecondary outcomes
1
Change in Mean Dizziness Handicap Inventory (DHI)
The (DHI) will be measured in subjects with unilateral vestibular hypo function to ensure symptoms are not worsening, but will not be measured in health subjects. This is a a 25 question scale ranging from 0-100 with 100 indicating worse dizziness.
Time frame
Baseline to 1 weekSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Rochester
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator
Source ClinicalTrials.gov